…BofA MERRILL LYNCH Dr. Alec W. Stranahan+1 646 743 2109 alec.stranahan@bofa.com Dr. Geoff Meacham+1 646 855 1004 geoff.meacham@bofa.com BLOOMBERG Cinney Zhangczhang429@bloomberg.net Sam Fazelimfazeli@bloomberg.net CANACCORD GENUITY Dr. John Newman+1…
…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi‑med.com. Tagrisso® and Iressa® are trademarks of the AstraZeneca PLC group of companies. Forward‑Looking…
…www.ckh.com.hk About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 470 scientists and…
…months ended 30 June 2019 respectively. For more information, please visit www.ckh.com.hk About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products….
…www.londonstockexchange.com. What is Nasdaq? The Nasdaq Stock Market, also known as simply Nasdaq, is an American stock exchange. It is the second-largest stock exchange by market capitalization in the world,…
…presentation will be available at www.chi-med.com. Surufatinib Phase I/Ib study in the US Safety and tolerability data of surufatinib in western patients were presented at ESMO 2019 as a…
…availability to ordinary people and enhance the quality of the patients’ lives. For more information, please visit: www.innoventbio.com. About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which…
…For more information, please visit: www.chi-med.com. FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of…
…drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. About AstraZeneca…
…a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com….
…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions…
…www.chi-med.com. About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff…
…a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com….
…Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:00pm PST in San Francisco, CA. The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder…
…Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Information about the Offering The Offering is being made pursuant to a shelf registration statement on…
…Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 Annie Cheng, Vice President, Corporate…
…of these adverse effects is feasible. For important safety information about fruquintinib, please see www.chi-med.com. About Other Fruquintinib Development Programs Global Development Phase I monotherapy in the U.S.: In…
…Global Select Market. For more information, please visit: www.chi-med.com. Information about the Offering The Offering is being made pursuant to a shelf registration statement on Form F-3 filed by…
…at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical…
…London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121…
…more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act…
…Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private…
…visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786…
…hand-foot syndrome and proteinuria. Clinically effective management of these adverse effects is feasible. For important safety information about fruquintinib, please see www.chi-med.com. About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative…
…is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking…
…Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries…
…Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee,…
…Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30am PST in San Francisco, CA. The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder…
…visit: www.chi-med.com. Information about the Offering The Offering will be made pursuant to a shelf registration statement on Form F-3 filed by Chi-Med with the United States Securities and…
…China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the…
…the website: www.generalatlantic.com. About Chi-Med Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and…
…in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within…
…at prospectus.cpdg@db.com. This announcement does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale…
…products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking…
…distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking…
…drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. About AstraZeneca…
…Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of…
…visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking…
…health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release…
…see www.chi-med.com. About Fruquintinib Development in CRC in China Clinical development of fruquintinib began in 2011 with an initial Phase I trial in 40 solid tumor patients, followed by a…
…www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786 David…
…Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new…
…www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements…
…commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com. About Inmagene Biopharmaceuticals Inmagene, with wholly owned subsidiaries in Shanghai, San Diego, and Hangzhou, is…
…real estate, infrastructure and fixed income are made by CPP Investments. Headquartered in Toronto, with offices in Hong Kong, London, Luxembourg, Mumbai, New York City, San Francisco, São Paulo and…
…to see if the firm is authorized by FCA. Report the call to the FCA by calling the FCA Consumer Helpline on 0800 111 6768 or complete the online boiler…
…(SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. Lancet Oncol. 2020; S1470-2045(20)30496-4. DOI: 10.1016/S1470-2045(20)30496-4. [3] According to Frost & Sullivan. In 2018,…
…placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. Lancet Oncol. 2020; S1470-2045(20)30496-4. DOI: 10.1016/S1470-2045(20)30496-4. [5] Xu J, Shen L, Bai C, et al. Surufatinib in advanced…
…access to treatment options. [4] Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead…
…can be found on the SEHK’s website at www.hkex.com.hk/Listing/Getting-Started/Listing-on-the-Main-Board. The Company’s listing application and the Offering is subject to, among other things, the completion of the review process of the…
…For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act…
…more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995….
…and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Tagrisso® and Iressa®…
…For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform…
…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121…
…multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor”…
…be accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to…
…of China. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities…
…in its home market of China. For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President +852 2121 8200 Annie Cheng, Vice President +1 (973)…
…ended 31 December 2019. For more information, please visit www.ckh.com.hk. About Chi-Med Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery…
…candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com. About Lilly Lilly is a…
…drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark…
…Summit held from November 18 to 20, 2020; and The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020. Further information are available at www.chi-med.com in…
…webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before…
…the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President +852 2121 8200…
…CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 U.K. &…
…prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 1). For more information, please visit: www.chi-med.com….
…information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 U.K. & International Media Enquiries Anthony Carlisle, Citigate Dewe Rogerson +44…
…accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to download…
…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements…
…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS Investor…
…the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the…
…Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward ‑looking statements within the meaning of the “safe harbor ” provisions of the U.S….
…more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act…
…London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe…
…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS Investor…
…AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance…
…is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Iressa® is a trademark of the AstraZeneca PLC group of companies….
…multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200…
…Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com….
…visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking…
…Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation…
…headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS…
…headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS…
…Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This…
…majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of…
…1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David Dible, Citigate Dewe Rogerson +44 7967 566…
…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor”…
…1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David Dible, Citigate Dewe Rogerson +44 7967 566…
…more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995….
…multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David…
…Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements…
…Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains…
…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. CONTACTS Investor…
…London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe…
…information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of…
…please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking…
…visit: www.chi-med.com. Forward Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements…
…1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform…
…Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements…